Originally from Elizabeth Métis Settlement and a long-time Cold Lake resident, Houle has worn many hats - public works ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...

EpiBiologics, a leader in tissue-selective extracellular protein degradation, today presented the first preclinical data on its EpiTAC bispecific antibody degrader of c-Met, a potential first-in-class ...

There may be “substantial delays” between when a drug is granted accelerated approval for a cancer indication, when negative trial results are released, and when the accelerated approval of the drug ...

The solid cash conversion allows Telix to internally fund organic growth and flexibility to pursue acquisitions. We expect the company to reinvest the majority of earnings into R&D. We forecast ...

Immune checkpoint inhibitor-based combinations have become the preferred first-line therapy for patients with metastatic clear cell renal cell carcinoma, but more than a third of eligible patients do ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared at the American Association for Cancer Research (AACR) ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal ...

Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

One local man fighting his toughest fight to beat Renal Clear Cell Carcinoma kidney cancer ...

“Our CB-SCs can target different compartments of the immune system, educating and correcting their dysfunctions at a fundamental level,” says Dr. Zhao. “This therapy has the potential to revolutionize ...

Explore medication options for kidney disease and potential side effects. Learn the best treatment options to slow ...